Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T‐cell subpopulations

Worsham, D. Nicole; Reems, Jo‐Anna; Szczepiórkowski, Zbigniew M.; McKenna, David H.; Leemhuis, Tom; Mathew, Aby J.; Cancelas, José A.

doi:10.1111/trf.14112

Cited by 28 publications

(26 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study found that the use of 10% DMSO for cryopreservation resulted in lower post-thaw viability for most lymphocyte subpopulations, especially CD3 + CD4 + and Tregs, as well as growth arrest of CD3 + cells in the G2/M phase [63]. These might account for loss of functional cells in cryopreserved T-cell product for immunotherapy.…”

Section: Emerging Approachesmentioning

confidence: 96%

Preservation of cell-based immunotherapies for clinical trials

Johnson

et al. 2019

Cytotherapy

Self Cite

View full text Add to dashboard Cite

Section: Emerging Approachesmentioning

confidence: 96%

Preservation of cell-based immunotherapies for clinical trials

Johnson

et al. 2019

Cytotherapy

Self Cite

View full text Add to dashboard Cite

“…Why CryoStor CS10 was better than 10% DMSO and 90% FCS is not evident from our experiments; however, several previous studies reported better cell survival fol-lowing cryopreservation in a variety of experimental systems with the use of CryoStor solutions over a number of other cryopreservation media. [9][10][11][12] CryoStor CS10 is a serum-free, protein-free, animal component-free intracellular-like defined cryopreservation medium containing 10% DMSO that has been designed to better maintain the ionic balance of cells at hypothermic and freezing temperatures and allow for more rapid recovery by reducing cryopreservation-induced stress and damage. [9][10][11][12] The design of CryoStor CS10 includes pH buffering, free radical scavenging, oncotic/osmotic support, energy substrates, and ionic concentrations for increased balance at ultralow temperatures.…”

Section: Discussionmentioning

confidence: 99%

Optimization of Viable Glioblastoma Cryopreservation for Establishment of Primary Tumor Cell Cultures

Valyi‐Nagy

Betsou²,

Susma

et al. 2021

Biopreservation and Biobanking

View full text Add to dashboard Cite

Background: Technologies related to the establishment of primary tumor cell cultures from solid tumors, including glioblastoma, are increasingly important to oncology research and practice. However, processing of fresh tumor specimens for establishment of primary cultures on the day of surgical collection is logistically difficult. The feasibility of viable cryopreservation of glioblastoma specimens, allowing for primary culture establishment weeks to months after surgical tumor collection and freezing, was demonstrated by Mullins et al. in 2013, with a success rate of 59% that was not significantly lower than that achieved with fresh tumor tissue. However, research targeting optimization of viable glioblastoma cryopreservation protocols for establishment of primary tumor cultures has been limited. Objectives: The objective of this study was to optimize glioblastoma cryopreservation methods for viable cryobanking and to determine if two-dimensional (2D) or three-dimensional (3D) culture conditions were more supportive of glioblastoma growth after thawing of frozen tumor specimens. Methods: Portions of eight human glioblastoma specimens were cryopreserved by four different protocols differing in the time of enzymatic digestion (before or after cryopreservation), and in the type of cryopreservation media (CryoStor CS10 or 10% dimethyl sulfoxide and 90% fetal calf serum). After 1 month, frozen tissues were thawed, enzymatically digested, if not digested before, and used for initiation of 2D or 3D primary tumor cultures to determine viability. Results: Among the tested cryopreservation and culturing protocols, the most efficient combinations of cryopreservation and culture were those associated with the use of CryoStor CS10 cryopreservation medium, enzymatic digestion before freezing, and 2D culturing after thawing with a successful culture rate of 8 out of 8 cases (100%). Two-dimensional cultures were in general more efficient for the support of tumor cell growth after thawing than 3D cultures. Conclusions: This study supports development of evidence-based viable glioblastoma cryopreservation methods for use in glioblastoma biobanking and research.

show abstract

“…Recently, Cryostor (BioLife Solutions), a commercially available cryoprotectant, has demonstrated comparable cell viability and postthaw recovery similar to our home‐brewed cocktail. A validation process is under way for its use in multi‐institutional trials as a standardized method . Cryopreserved products are stored in vials (Nunc Cryotube Vials, Roskilde) or in polyfluoroethylene bags (KryoSure, American Fluoroseal Corporation).…”

Section: Cryopreservationmentioning

confidence: 99%

How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?

et al. 2019

View full text Add to dashboard Cite

show abstract

Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T‐cell subpopulations

Abstract: This study has important implications in determining the best cryoprotectant solution for specific clinical applications in allogeneic immunotherapy.

Cited by 28 publications

References 38 publications

Preservation of cell-based immunotherapies for clinical trials

Preservation of cell-based immunotherapies for clinical trials

Optimization of Viable Glioblastoma Cryopreservation for Establishment of Primary Tumor Cell Cultures

How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?

Contact Info

Product

Resources

About